Protara Therapeutics rises as FDA allows mid-stage trial of cell therapy

Protara Therapeutics

02/05/2023 15:41

** Shares of therapy developer Protara Therapeutics Inc
 TARA.O  rise 3.3% to $3.12
    ** Co says it has received regulatory clearance from the
U.S. Food and Drug Administration (FDA) on its planned mid-stage
STARBORN-1 trial evaluating TARA-002
    ** TARA-002 is being studied as an investigational cell
therapy, for the treatment of pediatric patients with lymphatic
malformations
    ** The trial is expected to start in Q4
    ** Lymphatic malformations are clusters of enlarged and
misshaped lymphatic channels that do not work correctly
    ** Stock up 16.42% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))